RxDoctor Payments Data

Rita Falcone, MD

Cardiovascular Disease · West Chester, PANPI 1902966880

Payments from drug & device makers

$792in general payments, 2019–2025

Across 37 payments — averaging $21.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$325
  • Pfizer$124
  • Amgen$84
  • E.r. Squibb & Sons, L.L.C.$60
  • Kiniksa Pharmaceuticals International, PLC$53
  • Scpharmaceuticals Inc.$33
  • plus $112 from 5 others

What the payments were for

  • Food & beverage$792100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$792 in reported general payments places this provider in the 35th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

See all cardiovascular disease providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$238,492
Medicare patients
960
Services billed
2,499

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban263$275,763
XareltoRivaroxaban88$93,846
Repatha SureclickEvolocumab45$31,545
Metoprolol Succinate894$13,618
EntrestoSacubitril/Valsartan17$11,145
Praluent PenAlirocumab20$10,130
Rosuvastatin Calcium387$5,945
Atorvastatin Calcium352$3,842
Ezetimibe160$3,804
Ranolazine ErRanolazine20$2,825
Losartan Potassium199$1,988
Lisinopril263$1,884
Diltiazem 24hr Er (Cd)Diltiazem Hcl40$1,724
Amlodipine Besylate348$1,656
Nebivolol Hcl24$1,559

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$124$275,763263 claims
NovartisEntresto$325$11,14517 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

Other cardiovascular disease in West Chester

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →